Orlistat is contraindicated in patients with organic obesity such as hypothyroidism.
Hypothyroidism is hypothyroidism. In hypothyroidism, there is insufficient synthesis of thyroid hormones in the body, which can cause hypometabolic syndrome and may lead to symptoms such as weight gain, mucous edema, and constipation. Treatment of this obesity should actively treat the primary disease, such as oral levothyroxine sodium to supplement thyroxine, thus improving symptoms.
Orlistat belongs to the gastrointestinal lipase inhibitor, can inhibit the body’s absorption of fat, can be used to treat obesity or overweight and other conditions. However, it is not suitable for obesity caused by slow basal metabolic rate of hypothyroidism, and may also cause gastrointestinal dysfunction, which may aggravate gastrointestinal symptoms.
Therefore, patients with hypothyroidism are not recommended to take orlistat. In addition, orlistat is contraindicated in patients who are allergic to orlistat, those with chronic malabsorption syndrome, patients with cholestasis, and pregnant women.
Patients with hypothyroidism should actively cooperate with the doctor’s treatment, and should not blindly use Orlistat for treatment.